U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C6H13NO5.ClH
Molecular Weight 215.632
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GALACTOSAMINE HYDROCHLORIDE

SMILES

Cl.N[C@@H](C=O)[C@@H](O)[C@@H](O)[C@H](O)CO

InChI

InChIKey=CBOJBBMQJBVCMW-NQZVPSPJSA-N
InChI=1S/C6H13NO5.ClH/c7-3(1-8)5(11)6(12)4(10)2-9;/h1,3-6,9-12H,2,7H2;1H/t3-,4+,5+,6-;/m0./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C6H13NO5
Molecular Weight 179.1711
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Galactosamine is a hexosamine derived from galactose with the molecular formula C6H13NO5. A few amino sugars, including galactosamine, have been shown to kill tumors in the laboratory. It is unlikely to be used in cancer therapy, however. D-galactosamine is a hepatotoxic, or liver-damaging, agent. Researchers studying animal models of liver failure sometimes use D-galactosamine to induce liver damage. Galactosamine is also helpful for researchers studying agents that might protect the liver from damage.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
Biochemical characterization of the chondroitinase B active site.
2002-08-23
Influence of charge density, sulfate group position and molecular mass on adsorption of chondroitin sulfate onto coral.
2002-07
Role of arginine 292 in the catalytic activity of chondroitin AC lyase from Flavobacterium heparinum.
2002-06-03
Pleiotrophin/heparin-binding growth-associated molecule as a mitogen of rat hepatocytes and its role in regeneration and development of liver.
2002-06
Selective plasma filtration for treatment of fulminant hepatic failure induced by D-galactosamine in a pig model.
2002-06
Isolation of a glucosamine-specific kinase, a unique enzyme of Vibrio cholerae.
2002-05-03
Evaluation of drug-induced hepatotoxicity by plasma retinol binding protein.
2002-05-01
Hepatoprotective effect of majonoside R2, the major saponin from Vietnamese ginseng (Panax vietnamensis).
2002-05
TNF tolerance and cytotoxicity in the liver: the role of interleukin-1beta, inducible nitric oxide-synthase and heme oxygenase-1 in D-galactosamine-sensitized mice.
2002-05
Medicinal foodstuffs. XXIX. Potent protective effects of sesquiterpenes and curcumin from Zedoariae Rhizoma on liver injury induced by D-galactosamine/lipopolysaccharide or tumor necrosis factor-alpha.
2002-05
4-Nitrobenzylidene malononitrile reduces apoptosis-mediated liver injury in mice.
2002-05
[Polar constituents of the ascidia Botryllus schlosseri].
2002-04-19
Bacterial peptidoglycan-associated lipoprotein is released into the bloodstream in gram-negative sepsis and causes inflammation and death in mice.
2002-04-19
Purification of kappa-casien glycomacropeptide from sweet whey with undetectable level of phenylalanine.
2002-04-06
Antrodia camphorata polysaccharides exhibit anti-hepatitis B virus effects.
2002-03-19
The role of progenitor cells in repair of liver injury and in liver transplantation.
2002-03-19
Tumor necrosis factor-alpha-null mice are not resistant to cadmium chloride-induced hepatotoxicity.
2002-03-15
Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.
2002-03-15
Mechanisms of the protective effect of L-alanine to D-galactosamine-induced hepatocellular injury: comparative studies of L-alanine and pyruvate.
2002-03-08
PGE1 protection against apoptosis induced by D-galactosamine is not related to the modulation of intracellular free radical production in primary culture of rat hepatocytes.
2002-03
Protective effect of pretreatment with low-dose lipopolysaccharide on D-galactosamine-induced acute liver failure.
2002-03
Diethyldithiocarbamate inhibition of galactosamine-induced hepatitis in rats.
2002-03
A20 protects mice from D-galactosamine/lipopolysaccharide acute toxic lethal hepatitis.
2002-03
Hepatoprotective principles from the flowers of Tilia argentea (linden): structure requirements of tiliroside and mechanisms of action.
2002-03
Effect of structure modification of chondroitin sulfate C on its enantioselectivity to basic drugs in capillary electrophoresis.
2002-02-22
Purification, characterization, and cDNA cloning of alpha-N-acetylgalactosamine-specific lectin from starfish, Asterina pectinifera.
2002-02
Protective effect of Linomide on TNF-alpha-induced hepatic injury.
2002-02
Sensitive markers used to identify compounds that trigger apoptosis in cultured hepatocytes.
2002-02
[Isolation and characterization of Cytophaga lytica lipopolysaccharide].
2002-01-12
Messenger RNA profiles in liver injury and stress: a comparison of lethal and nonlethal rat models.
2002-01-11
[Diversity in the monosaccharide composition of antigenic polysaccharides from proteobacteria Pseudoalteromonas and Marinomonas genera].
2002-01-05
Effects of dietary protein of proso millet on liver injury induced by D-galactosamine in rats.
2002-01
Leukocyte recruitment in hepatic injury: selectin-mediated leukocyte rolling is a prerequisite for CD18-dependent firm adhesion.
2002-01
Endothelin is an important determinant of renal function in a rat model of acute liver and renal failure.
2002-01
Purification and characterization of a human pancreatic adenocarcinoma mucin.
2002-01
O(2)-Vinyl 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate protection against D-galactosamine/endotoxin-induced hepatotoxicity in mice: genomic analysis using microarrays.
2002-01
Detection of two distinct transporter systems for 2-deoxyglucose uptake by the opportunistic pathogen Pneumocystis carinii.
2001-12-01
Aggresome formation in liver cells in response to different toxic mechanisms: role of the ubiquitin-proteasome pathway and the frameshift mutant of ubiquitin.
2001-12
Enhanced biorecognition and internalization of HPMA copolymers containing multiple or multivalent carbohydrate side-chains by human hepatocarcinoma cells.
2001-11-22
Syntheses and activities as trehalase inhibitors of N-arylglycosylamines derived from fluorinated anilines.
2001-11-01
Protection against Fas-mediated and tumor necrosis factor receptor 1-mediated liver injury by blockade of FADD without loss of nuclear factor-kappaB activation.
2001-11
Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.
2001-10-18
Protective effects of Indigofera tinctoria L. against D-Galactosamine and carbon tetrachloride challenge on 'in situ' perfused rat liver.
2001-10
Animal models of fulminant hepatic failure: need to test liver support devices.
2001-10
Rapid analysis of amino sugars by microchip electrophoresis with laser-induced fluorescence detection.
2001-10
Involvement of a serine protease, but not of neutrophil elastase, in tumor necrosis factor-induced lethal hepatitis and induction of platelet-activating factor.
2001-10
Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer-doxorubicin-galactosamine conjugate antitumour agent.
2001-09
N-alkyl-3-decarboxy-3-hydroxymethylsiastatin B, a new family of glycosidase inhibitors of gem-diamine 1-N-iminosugars.
2001
Protective effect of wogonin on endotoxin-induced lethal shock in D-galactosamine-sensitized mice.
2001
Genetic determinants of lipopolysaccharide and D-galactosamine-mediated hepatocellular apoptosis and lethality.
2001
Patents

Sample Use Guides

Wistar female rats received 1.4 g/kg of d-galactosamine intraperitoneally
Route of Administration: Intraperitoneal
Preincubation of human apoptotic eosinophils with galactosamine (25 mmol/L) significantly inhibited their uptake by both resting and IL-1a–stimulated human small airway epithelial cells (SAEC).
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:57:28 GMT 2025
Edited
by admin
on Mon Mar 31 21:57:28 GMT 2025
Record UNII
U51H7Z9859
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
D-GALACTOSAMINE HYDROCHLORIDE
MI  
Preferred Name English
GALACTOSAMINE HYDROCHLORIDE
USP-RS  
Systematic Name English
D-GALACTOSAMINE HYDROCHLORIDE [MI]
Common Name English
2-AMINO-2-DEOXY-D-GALACTOSE, HYDROCHLORIDE
Systematic Name English
D-GALACTOSE, 2-AMINO-2-DEOXY-, HYDROCHLORIDE (1:1)
Systematic Name English
GALACTOSAMINE HYDROCHLORIDE [USP-RS]
Common Name English
CHONDROSAMINE HYDROCHLORIDE
Common Name English
Code System Code Type Description
CAS
1772-03-8
Created by admin on Mon Mar 31 21:57:28 GMT 2025 , Edited by admin on Mon Mar 31 21:57:28 GMT 2025
PRIMARY
PUBCHEM
74493
Created by admin on Mon Mar 31 21:57:28 GMT 2025 , Edited by admin on Mon Mar 31 21:57:28 GMT 2025
PRIMARY
EPA CompTox
DTXSID4031356
Created by admin on Mon Mar 31 21:57:28 GMT 2025 , Edited by admin on Mon Mar 31 21:57:28 GMT 2025
PRIMARY
MERCK INDEX
m5634
Created by admin on Mon Mar 31 21:57:28 GMT 2025 , Edited by admin on Mon Mar 31 21:57:28 GMT 2025
PRIMARY Merck Index
FDA UNII
U51H7Z9859
Created by admin on Mon Mar 31 21:57:28 GMT 2025 , Edited by admin on Mon Mar 31 21:57:28 GMT 2025
PRIMARY
RS_ITEM_NUM
1287722
Created by admin on Mon Mar 31 21:57:28 GMT 2025 , Edited by admin on Mon Mar 31 21:57:28 GMT 2025
PRIMARY
ECHA (EC/EINECS)
217-198-1
Created by admin on Mon Mar 31 21:57:28 GMT 2025 , Edited by admin on Mon Mar 31 21:57:28 GMT 2025
PRIMARY